Alpha-cell Function

β-cell function preservation after 3.5 years of intensive diabetes therapy

Top

Harrison LB, Adams Huet B, Raskin P, Lingvay I. Beta cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412. To assess beta-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.

DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction

Top

Continuous coverage of ADA 2012. Perreault L, Pan Q, Mather KJ, et al; for the Diabetes Prevention Program Research Group. DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction. Lancet. 2012;379(9833):2243-2251. This report sought to quantify and predict diabetes risk reduction during the long-term follow-up to the Diabetes Prevention Program (DPP), the Diabetes Prevention Program Outcomes Study (DPPOS).

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes

Top

Defronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP 4 inhibitor alogliptin combined with pioglitazone, in metformin treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 Mar 14. Epub ahead of print. Optimal management of type 2 diabetes remains an elusive goal. Combination therapy addressing the core defects of impaired insulin secretion and insulin resistance shows promise in maintaining glycemic control.

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone

Top

Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone a 52 week, randomized, double blind, active controlled, parallel group study. Diabetes Obes Metab. 2011;13(12):1088-1096. AIM: To assess the efficacy and safety of adding alogliptin versus uptitrating pioglitazone in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone.

Glucagon-like peptide analogues for type 2 diabetes mellitus

Top

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD006423. Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response to ingested nutrients.

The safety of incretin-based therapies--review of the scientific evidence

Top

Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab. 2011;96(7):2027-31. Antidiabetic therapies based on potentiation of incretin action are now widely used; however, understanding of their long-term safety remains incomplete. Evidence Acquisition: We searched articles in PubMed for data assessing the safety of incretin-based therapies.

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy

Top

Dicembrini I, Pala L, Rotella CM. From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy. Exp Diabetes Res. 2011;2011:898913. Epub 2011 Jun 23. Promoting long-term adherence to lifestyle modification and choice of antidiabetic agent with low hypoglycemia risk profile and positive weight profile could be the most effective strategy in achieving sustained glycemic control and in reducing comorbidities.

Type 2 diabetes can be prevented with early pharmacological intervention

Top

DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011;34 Suppl 2:S202-9. In the U.S., ∼ 21 × 10(6) individuals have type 2 diabetes, and twice as many have impaired glucose tolerance (IGT). Approximately 40-50% of individuals with IGT will progress to type 2 diabetes over their lifetime. Therefore, treatment of high-risk individuals with IGT to prevent type 2 diabetes has important medical, economic, social, and human implications.

4 Wks of Treatment w/ Liraglutide Reduces Insulin Dose w/o Loss of Glycemic Control in Type 1 Diabetic Patients w/ & w/o Residual β-Cell Function

Top

Kielgast U, Krarup T, Holst JJ, Madsbad S. Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual {beta}-Cell Function. Diabetes Care. 2011;34(7):1463-8. To investigate the effect of 4 weeks of treatment with liraglutide on insulin dose and glycemic control in type 1 diabetic patients with and without residual β-cell function.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes

Top

Jellinger PS. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Postgrad Med. 2011 Jan;123(1):53-65. Glucose homeostasis is regulated by a complex interaction of hormones, principally including insulin, glucagon, amylin, and the incretins. Glucagon, cortisol, catecholamines, and growth hormone serve as the classic glucose counterregulatory hormones.

1 2 3 4 5 6 7 8 9 10  ... Next